Trial Watch: Immunotherapy plus radiation therapy for oncological indications.

An epigenetic modifier triggers therapeutic immune responses against breast cancer. Oncoimmunology (2017) 0.75

Barriers to Radiation-Induced In Situ Tumor Vaccination. Front Immunol (2017) 0.75

Immune recognition of irradiated cancer cells. Immunol Rev (2017) 0.75

IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 32.41

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med (2004) 30.26

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science (2005) 23.44

Regulation of p53 stability by Mdm2. Nature (1997) 18.20

Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol (2007) 16.55

Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin (2012) 14.47

Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys (1991) 13.16

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol (2003) 11.94

p53 in health and disease. Nat Rev Mol Cell Biol (2007) 11.33

Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science (2009) 10.78

PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature (2014) 10.39

Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med (2014) 10.38

Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med (2015) 10.12

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med (2014) 10.10

Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med (2015) 8.64

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet (2014) 8.63

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature (2015) 7.49

Immunogenic cell death in cancer therapy. Annu Rev Immunol (2012) 6.59

Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev (2011) 5.64

Cancer immunotherapy via dendritic cells. Nat Rev Cancer (2012) 5.37

Molecular mechanisms of cisplatin resistance. Oncogene (2011) 5.20

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol (2015) 4.85

Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res (2009) 4.58

Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys (2010) 4.33

Treatment of vulvar intraepithelial neoplasia with topical imiquimod. N Engl J Med (2008) 4.33

Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys (2004) 4.29

Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer (2012) 3.76

Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity (2013) 3.73

Effects of radiation on normal tissue: consequences and mechanisms. Lancet Oncol (2003) 3.70

Brain tumour cells interconnect to a functional and resistant network. Nature (2015) 3.59

Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol (2015) 3.57

Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol (2011) 3.40

Radiation-induced bystander signalling in cancer therapy. Nat Rev Cancer (2009) 3.31

Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol (2000) 3.24

Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21

Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial. Lancet Oncol (2014) 3.12

Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst (2013) 3.07

Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest (2014) 3.06

Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol (2015) 2.98

The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer (2005) 2.92

Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell (2013) 2.89

Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study. Lancet Oncol (2014) 2.81

In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol (2009) 2.76

Hypoxic radiosensitization: adored and ignored. J Clin Oncol (2007) 2.67

Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. Cell Death Differ (2014) 2.66

Oncogenic stress sensed by the immune system: role of natural killer cell receptors. Nat Rev Immunol (2009) 2.44

Exosome transfer from stromal to breast cancer cells regulates therapy resistance pathways. Cell (2014) 2.41

Metabolic targets for cancer therapy. Nat Rev Drug Discov (2013) 2.32

Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology (2014) 2.30

An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res (2013) 2.30

STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. Immunity (2014) 2.28

Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation. Science (2015) 2.20

Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study. Lancet Oncol (2015) 2.17

Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. Lancet Oncol (2011) 2.16

Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. Nat Rev Cancer (2009) 2.13

Radiation-induced bystander effects--implications for cancer. Nat Rev Cancer (2004) 2.08

Emerging role of damage-associated molecular patterns derived from mitochondria in inflammation. Trends Immunol (2011) 2.05

Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair. Nature (2015) 2.04

Factors underlying the cell growth-related bystander responses to alpha particles. Cancer Res (2000) 2.00

Radiation oncology: a century of achievements. Nat Rev Cancer (2004) 1.98

Inside and out: the activities of senescence in cancer. Nat Rev Cancer (2014) 1.96

Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene (2008) 1.94

Mechanism of radiation-induced bystander effect: role of the cyclooxygenase-2 signaling pathway. Proc Natl Acad Sci U S A (2005) 1.92

Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma. Blood (2012) 1.92

Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth. J Invest Dermatol (2012) 1.90

Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. Cancer Cell (2015) 1.85

American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol (2008) 1.80

Mathematical modeling of PDGF-driven glioblastoma reveals optimized radiation dosing schedules. Cell (2014) 1.79

Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology (2012) 1.78

Radiation as an immunological adjuvant: current evidence on dose and fractionation. Front Oncol (2012) 1.76

Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study. Lancet Oncol (2015) 1.75

Systems biology of cisplatin resistance: past, present and future. Cell Death Dis (2014) 1.74

Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol (2015) 1.74

Regulation of NK cell responsiveness to achieve self-tolerance and maximal responses to diseased target cells. Immunol Rev (2008) 1.74

Can we reduce the incidence of second primary malignancies occurring after radiotherapy? A critical review. Radiother Oncol (2009) 1.65

Second malignant neoplasms and cardiovascular disease following radiotherapy. J Natl Cancer Inst (2012) 1.64

Nitric oxide-mediated signaling in the bystander response of individually targeted glioma cells. Cancer Res (2003) 1.64

Extracellular factor(s) following exposure to alpha particles can cause sister chromatid exchanges in normal human cells. Cancer Res (1997) 1.61

Phase 1 study of stereotactic body radiotherapy and interleukin-2--tumor and immunological responses. Sci Transl Med (2012) 1.61

Type I interferons in anticancer immunity. Nat Rev Immunol (2015) 1.57

Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev (2011) 1.55

Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects. J Clin Invest (2012) 1.55

Classification of current anticancer immunotherapies. Oncotarget (2014) 1.55

Imiquimod in the treatment of breast cancer skin metastasis. J Clin Oncol (2014) 1.51

The development of immunoconjugates for targeted cancer therapy. Nat Rev Clin Oncol (2014) 1.49

Castration radiosensitizes prostate cancer tissue by impairing DNA double-strand break repair. Sci Transl Med (2015) 1.46

Immunological Characterization of Whole Tumour Lysate-Loaded Dendritic Cells for Cancer Immunotherapy. PLoS One (2016) 1.41

Radiotherapy-related fatigue. Crit Rev Oncol Hematol (2002) 1.40

Abscopal effect in a patient with melanoma. N Engl J Med (2012) 1.39

A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int (2011) 1.37

PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors. J Immunother (2015) 1.35

Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death. Oncoimmunology (2014) 1.35

The controversial abscopal effect. Cancer Treat Rev (2005) 1.34

Organelle-specific initiation of cell death. Nat Cell Biol (2014) 1.33

Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer. Clin Cancer Res (2012) 1.31

Trial Watch: Anticancer radioimmunotherapy. Oncoimmunology (2013) 1.31

TGFβ1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo. Clin Cancer Res (2011) 1.30

Alpha particles induce the production of interleukin-8 by human cells. Radiat Res (1999) 1.30

Prognostic and predictive values of the immunoscore in patients with rectal cancer. Clin Cancer Res (2014) 1.29

Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PLoS One (2014) 1.26

Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy. Oncoimmunology (2015) 0.85

Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy. Oncoimmunology (2016) 0.84

Trial Watch-Oncolytic viruses and cancer therapy. Oncoimmunology (2015) 0.83

Trial Watch-Immunostimulation with cytokines in cancer therapy. Oncoimmunology (2015) 0.77